Insulet
PODD
134.36
-0.37
-0.27%
Insulet
US · PODD
#1561 by market cap
Listed 1970
134.36
-0.37
-0.27%
Live - 5344 symbols - heartbeat 214s ago
· 2026-10-08 04:01
Pre-market
134.30
-0.04%
After-hours
134.36
0.00%
- Market cap
- 9.32B
- P/E (TTM)i
- 25.21
- P/Bi
- 6.55
- EPSi
- 3.48
- Div yieldi
- 0.00%
- 52W posi
- 3%
Reader sentiment
Are you bullish or bearish on PODD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.27, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +30.73% YoY
Margins
- Gross margin
- 71.63%
- Operating margin
- 17.50%
- Net margin
- 9.12%
Key ratios & quality
- Enterprise valuei
- 9.55B
- PEG ratioi
- 0.09
- Altman Z-Scorei
- 5.27
PEG uses trailing P/E against the 3-year net income growth rate (277.32%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 563.80M | 738.20M | 904.40M | 1.10B | 1.31B | 1.70B | 2.07B | 2.71B |
| Gross profit | 370.20M | 480.30M | 582.30M | 752.10M | 805.60M | 1.16B | 1.45B | 1.94B |
| Selling & admin expenses | 248.00M | 298.00M | 384.00M | 466.00M | 587.80M | 734.80M | 917.20M | 1.17B |
| Research & development | 94.80M | 132.30M | 146.80M | 160.10M | 180.20M | 205.00M | 219.60M | 301.10M |
| Operating profit | 27.40M | 50.00M | 51.50M | 126.00M | 37.60M | 220.10M | 308.90M | 473.80M |
| Pretax profit | 5.20M | 14.50M | 9.70M | 20.50M | 9.80M | 214.70M | 300.20M | 339.50M |
| Tax | 1.90M | 2.90M | 2.90M | 3.70M | 5.20M | 8.30M | -118.10M | 92.40M |
| Net profit | 3.30M | 11.60M | 6.80M | 16.80M | 4.60M | 206.30M | 418.30M | 247.10M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 3 | 6 | 4 |
| Diluted EPS | 0.05 | 0.19 | 0.10 | 0.24 | 0.07 | 2.94 | 5.78 | 3.48 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 569.00M | 649.10M | 706.30M | 783.80M | 761.70M | 801.70M |
| Gross profit | 409.00M | 452.20M | 510.10M | 568.60M | 529.10M | 562.60M |
| Selling & admin expenses | 260.70M | 257.70M | 315.20M | 331.40M | 317.20M | 344.80M |
| Research & development | 59.60M | 73.40M | 77.20M | 90.90M | 89.70M | 88.10M |
| Operating profit | 88.70M | 121.10M | 117.70M | 146.30M | 122.20M | 129.70M |
| Pretax profit | 48.20M | 28.40M | 122.80M | 140.20M | 113.00M | 118.70M |
| Tax | 12.70M | 5.90M | 35.20M | 38.50M | 21.90M | 23.70M |
| Net profit | 35.40M | 22.50M | 87.60M | 101.60M | 91.10M | 95.00M |
| Basic EPS | 1 | 0 | 1 | 1 | 1 | 1 |
| Diluted EPS | 0.50 | 0.32 | 1.24 | 1.44 | 1.30 | 1.37 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 461.30M | 591.00M | 1.25B | 1.33B | 1.31B | 1.58B | 1.89B | 1.91B |
| Cash & ST investments | 288.90M | 376.10M | 947.60M | 790.00M | 674.20M | 704.20M | 953.30M | 716.10M |
| Inventory | 71.40M | 101.00M | 154.30M | 303.20M | 346.80M | 402.60M | 430.40M | 452.60M |
| Total assets | 928.70M | 1.14B | 1.87B | 2.05B | 2.25B | 2.59B | 3.09B | 3.19B |
| Total current liabilities | 115.70M | 157.70M | 207.80M | 228.80M | 364.70M | 451.20M | 528.40M | 680.10M |
| Short-term debt | -- | -- | 15.60M | 25.10M | 27.50M | 49.40M | 83.80M | 18.40M |
| Long-term debt | 592.00M | 887.90M | 1.04B | 1.25B | 1.37B | 1.37B | 1.30B | 930.80M |
| Total liabilities | 716,600,000.00 | 1,067,000,000.00 | 1,269,300,000.00 | 1,492,500,000.00 | 1,774,700,000.00 | 1,855,500,000.00 | 1,876,100,000.00 | 1,675,100,000.00 |
| Total equity | 212.10M | 75.90M | 603.60M | 556.30M | 476.40M | 732.70M | 1.21B | 1.52B |
| Retained earnings | -683.60M | -672.00M | -666.30M | -649.50M | -584.30M | -378.00M | 40.30M | 287.40M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 2.33B | 2.28B | 1.86B | 1.91B | 1.71B | 1.85B |
| Cash & ST investments | 1.28B | 1.12B | 757.50M | 716.10M | 480.40M | 534.90M |
| Inventory | 440.80M | 447.00M | 446.30M | 452.60M | 462.50M | 484.80M |
| Total assets | 3.52B | 3.47B | 3.03B | 3.19B | 2.99B | 3.17B |
| Total current liabilities | 520.40M | 1.01B | 647.70M | 680.10M | 687.50M | 744.20M |
| Short-term debt | 83.10M | 460.70M | 79.90M | 18.40M | 18.60M | 18.90M |
| Long-term debt | 1.61B | 939.00M | 934.90M | 930.80M | 929.50M | 929.50M |
| Total liabilities | 2,186,600,000.00 | 2,006,900,000.00 | 1,645,000,000.00 | 1,675,100,000.00 | 1,684,600,000.00 | 1,742,900,000.00 |
| Total equity | 1.33B | 1.46B | 1.38B | 1.52B | 1.30B | 1.42B |
| Retained earnings | 75.70M | 98.20M | 185.80M | 287.40M | 378.50M | 473.50M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 35.90M | 98.40M | 84.00M | -68.10M | 119.00M | 145.70M | 430.20M | 569.30M |
| Depreciation & amortization | 15.60M | 27.90M | 55.40M | 57.40M | 63.20M | 72.80M | 80.80M | 90.40M |
| Free cash flow | -126.50M | -72.50M | -82.50M | -190.80M | -38.30M | 36.50M | 296.20M | 349.90M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 477.50M | -- | -- | 0 | 0 | -59.60M |
| Ending cash balance | 113.90M | 213.70M | 922.00M | 806.40M | 689.70M | 704.20M | 953.40M | 716.10M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 63.80M | 196.50M | 125.70M | 183.30M | 113.80M | 88.40M |
| Depreciation & amortization | 21.70M | 22.30M | 22.00M | 24.40M | 26.20M | 26.70M |
| Free cash flow | 48.10M | 173.30M | 94.60M | 33.90M | 86.00M | 51.10M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | -30.10M | -29.50M | 0 | -300.00M | 0 |
| Ending cash balance | 1.28B | 1.12B | 757.40M | 716.10M | 480.40M | 534.90M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 1.78 | 8.06 | 2.00 | 2.90 | 0.89 | 34.12 | 43.03 | 18.12 |
| ROA %i | 0.38 | 1.12 | 0.45 | 0.86 | 0.21 | 8.53 | 14.74 | 7.87 |
| ROIC %i | 2.26 | 3.49 | 2.76 | 3.66 | 1.20 | 10.61 | 17.71 | 10.46 |
| 5-year avg ROE %i | -51.20 | -39.70 | -14.35 | -1.89 | 3.13 | 9.59 | 16.59 | 19.81 |
| EBIT margin %i | 6.05 | 6.27 | 6.07 | 7.16 | 3.22 | 14.78 | 16.55 | 14.73 |
| FCF / sales %i | -- | -- | -- | -- | -- | 2.15 | 14.30 | 12.92 |
| Current ratioi | 3.99 | 3.75 | 6.01 | 5.81 | 3.60 | 3.51 | 3.58 | 2.81 |
| Quick ratioi | 3.16 | 2.82 | 5.02 | 4.16 | 2.41 | 2.36 | 2.50 | 1.81 |
| Debt / assetsi | 63.75 | 77.69 | 56.56 | 62.18 | 62.27 | 54.70 | 44.69 | 29.75 |
| LT debt / equityi | 279.11 | 1,169.83 | 172.91 | 224.48 | 288.48 | 186.49 | 106.97 | 61.43 |
| Interest coveragei | 1.18 | 1.46 | 1.21 | 1.35 | 1.30 | 6.93 | 8.03 | 6.72 |
| Revenue CAGR (3Y) %i | 28.80 | 26.23 | 24.93 | 24.91 | 20.92 | 23.34 | 23.54 | 27.54 |
| Net income CAGR (3Y) %i | -- | -- | -- | 72.03 | -26.53 | 211.89 | 192.01 | 277.32 |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 37.92 | 19.19 | 19.68 | 18.12 | 23.00 | 26.02 |
| ROA %i | 13.10 | 7.44 | 8.13 | 7.87 | 9.31 | 11.31 |
| ROIC %i | 15.44 | 9.27 | 10.46 | 10.46 | 12.49 | 15.39 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 15.22 | 13.58 | 14.43 | 14.73 | 16.17 | 18.13 |
| FCF / sales %i | 12.77 | 16.62 | 16.16 | 12.92 | 13.37 | 8.70 |
| Current ratioi | 4.47 | 2.26 | 2.87 | 2.81 | 2.49 | 2.48 |
| Quick ratioi | 3.24 | 1.55 | 1.88 | 1.81 | 1.49 | 1.51 |
| Debt / assetsi | 48.20 | 40.35 | 33.50 | 29.75 | 31.74 | 29.96 |
| LT debt / equityi | 121.16 | 64.21 | 67.54 | 61.43 | 71.36 | 65.36 |
| Interest coveragei | 8.12 | 6.44 | 6.85 | 6.72 | 7.23 | 9.41 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Omnipod products is the largest reported line at 99.28% of revenue, across 2 reported segments.
- The next-largest line, Drug Delivery, is a distant second at 0.72% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Omnipod products99.28%
Drug Delivery0.72%
Quote time 2026-10-08 04:01:04 · For reference only, not investment advice and not tailored to your situation.